2bpm: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2bpm.gif|left|200px]] | [[Image:2bpm.gif|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_2bpm", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
| | --> | ||
| | {{STRUCTURE_2bpm| PDB=2bpm | SCENE= }} | ||
}} | |||
'''STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529''' | '''STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529''' | ||
| Line 49: | Line 46: | ||
[[Category: Varasi, M.]] | [[Category: Varasi, M.]] | ||
[[Category: Vulpetti, A.]] | [[Category: Vulpetti, A.]] | ||
[[Category: | [[Category: Cell division]] | ||
[[Category: | [[Category: Cyclin]] | ||
[[Category: | [[Category: Phosphorylation]] | ||
[[Category: | [[Category: Protein kinase]] | ||
[[Category: | [[Category: Serine/threonine-protein kinase]] | ||
[[Category: | [[Category: Transferase]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 20:37:01 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
Revision as of 20:37, 3 May 2008
STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
OverviewOverview
Inhibitors of cyclin-dependent kinases (CDK) such as CDK2/cyclin A-E are currently undergoing clinical trials to verify their potential as new anticancer agents. In a previous article we described the lead discovery process of a 3-aminopyrazole class of CDK2/cyclin A-E inhibitors. The endpoint of this process was PNU-292137, a compound endowed with in vivo antitumor activity in a mouse tumor xenograft model. We optimized this lead compound to improve some physicochemical properties, notably solubility and plasma protein binding. This lead optimization process brought us to the discovery of (2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]p ropanamide (PHA-533533, 13), a compound with a balanced activity vs druglike profile. Compound 13 inhibited CDK2/cyclin A with a K(i) of 31 nM, counteracting tumor cell proliferation of different cell lines with an IC(50) in the submicromolar range. Solubility was improved more than 10 times over the starting lead, while plasma protein binding was decreased from 99% to 74%. With exploitation of this globally enhanced in vitro profile, 13 was more active than PNU-292137 in vivo in the A2780 xenograft model showing a tumor growth inhibition of 70%. Proof of mechanism of action was obtained in vivo by immunohistochemical analysis of tumor slices of 13-treated vs untreated animals.
About this StructureAbout this Structure
2BPM is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization., Pevarello P, Brasca MG, Orsini P, Traquandi G, Longo A, Nesi M, Orzi F, Piutti C, Sansonna P, Varasi M, Cameron A, Vulpetti A, Roletto F, Alzani R, Ciomei M, Albanese C, Pastori W, Marsiglio A, Pesenti E, Fiorentini F, Bischoff JR, Mercurio C, J Med Chem. 2005 Apr 21;48(8):2944-56. PMID:15828833 Page seeded by OCA on Sat May 3 20:37:01 2008
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Homo sapiens
- Non-specific serine/threonine protein kinase
- Protein complex
- Albanese, C.
- Alzani, R.
- Bischoff, J R.
- Brasca, M G.
- Cameron, A.
- Ciomei, M.
- Fiorentini, F.
- Fogliatto, G.
- Longo, A.
- Marsiglio, A.
- Mercurio, C.
- Nesi, M.
- Orsini, P.
- Orzi, F.
- Pastori, W.
- Pesenti, E.
- Pevarello, P.
- Piutti, C.
- Roletto, F.
- Sansonna, P.
- Traquandi, G.
- Varasi, M.
- Vulpetti, A.
- Cell division
- Cyclin
- Phosphorylation
- Protein kinase
- Serine/threonine-protein kinase
- Transferase